Compare CATO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | ICCC |
|---|---|---|
| Founded | 1946 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.0M | 64.0M |
| IPO Year | 1994 | 1995 |
| Metric | CATO | ICCC |
|---|---|---|
| Price | $2.87 | $8.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.2K | 26.3K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.04 | 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $653,812,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.62 | ★ 51.64 |
| 52 Week Low | $2.41 | $4.52 |
| 52 Week High | $4.92 | $9.08 |
| Indicator | CATO | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 61.18 |
| Support Level | $2.90 | $5.78 |
| Resistance Level | $3.20 | N/A |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 36.12 | 54.81 |
The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.